Join
Live feed
·
PRReleasevia Quantisnow
Contineum Therapeutics Inc. logo

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

ByQuantisnow·Wall Street's wire, on your screen.
CTNM· Contineum Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTNM (Contineum Therapeutics Inc.) and more on Quantisnow.